Tak KY, Jang B, Lee SK, et al. - Researchers focused on the potential role of Mac-2-binding protein glycosylation isomer (M2BPGi) in predicting clinical results of patients who received transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Participants were 226 in total, and serum M2BPGi was recorded at baseline. Significantly better overall survival (OS) and progression-free survival (PFS) were noted in patients with low M2BPGi levels vs those with high M2BPGi levels. Findings indicate the usefulness of serum M2BPGi concentration as a prognostic indicator of PFS and OS in TACE-treated HCC cases, as well as recurrent cases, which cannot be predicted with the hepatoma arterial embolization prognostic (HAP) score. An enhanced detection of TACE-preferred cases was offered by the combination of M2BPGi and the HAP score.